These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 27813323)

  • 1. Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.
    Wadajkar AS; Dancy JG; Hersh DS; Anastasiadis P; Tran NL; Woodworth GF; Winkles JA; Kim AJ
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2017 Jul; 9(4):. PubMed ID: 27813323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment.
    Ganipineni LP; Danhier F; Préat V
    J Control Release; 2018 Jul; 281():42-57. PubMed ID: 29753958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing nanomedicine for therapeutic intervention in glioblastoma.
    Gutkin A; Cohen ZR; Peer D
    Expert Opin Drug Deliv; 2016 Nov; 13(11):1573-1582. PubMed ID: 27292970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
    Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
    Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide nanoparticles for targeted glioblastoma therapy.
    Fang C; Wang K; Stephen ZR; Mu Q; Kievit FM; Chiu DT; Press OW; Zhang M
    ACS Appl Mater Interfaces; 2015 Apr; 7(12):6674-82. PubMed ID: 25751368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.
    Choudhury H; Pandey M; Chin PX; Phang YL; Cheah JY; Ooi SC; Mak KK; Pichika MR; Kesharwani P; Hussain Z; Gorain B
    Drug Deliv Transl Res; 2018 Oct; 8(5):1545-1563. PubMed ID: 29916012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
    Kim SS; Harford JB; Pirollo KF; Chang EH
    Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles.
    Bouras A; Kaluzova M; Hadjipanayis CG
    J Neurooncol; 2015 Aug; 124(1):13-22. PubMed ID: 25981803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles.
    Miranda A; Blanco-Prieto MJ; Sousa J; Pais A; Vitorino C
    Int J Pharm; 2017 Oct; 531(1):389-410. PubMed ID: 28801108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticles: Novel vehicles in treatment of Glioblastoma.
    Pourgholi F; Hajivalili M; Farhad JN; Kafil HS; Yousefi M
    Biomed Pharmacother; 2016 Feb; 77():98-107. PubMed ID: 26796272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma.
    Bastiancich C; Danhier P; Préat V; Danhier F
    J Control Release; 2016 Dec; 243():29-42. PubMed ID: 27693428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic Lymphoma Kinase in Glioblastoma: Detection/Diagnostic Methods and Therapeutic Options.
    Kalamatianos T; Denekou D; Stranjalis G; Papadimitriou E
    Recent Pat Anticancer Drug Discov; 2018; 13(2):209-223. PubMed ID: 29336268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Challenges and Opportunities in Treating Glioblastoma.
    Shergalis A; Bankhead A; Luesakul U; Muangsin N; Neamati N
    Pharmacol Rev; 2018 Jul; 70(3):412-445. PubMed ID: 29669750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach.
    Agarwal S; Muniyandi P; Maekawa T; Kumar DS
    Int J Pharm; 2018 Nov; 551(1-2):339-361. PubMed ID: 30236647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells.
    Schneider CS; Perez JG; Cheng E; Zhang C; Mastorakos P; Hanes J; Winkles JA; Woodworth GF; Kim AJ
    Biomaterials; 2015 Feb; 42():42-51. PubMed ID: 25542792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanocarrier-based drug combination therapy for glioblastoma.
    Zhao M; van Straten D; Broekman MLD; Préat V; Schiffelers RM
    Theranostics; 2020; 10(3):1355-1372. PubMed ID: 31938069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.
    Wiwatchaitawee K; Quarterman JC; Geary SM; Salem AK
    AAPS PharmSciTech; 2021 Feb; 22(2):71. PubMed ID: 33575970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CREKA peptide-conjugated dendrimer nanoparticles for glioblastoma multiforme delivery.
    Zhao J; Zhang B; Shen S; Chen J; Zhang Q; Jiang X; Pang Z
    J Colloid Interface Sci; 2015 Jul; 450():396-403. PubMed ID: 25863222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of nanoparticles for drug delivery in glioblastoma multiforme.
    Jain KK
    Expert Rev Neurother; 2007 Apr; 7(4):363-72. PubMed ID: 17425491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.